FR2741088B1 - Methode de traitement de maladies neurodegeneratives mettant en oeuvre un anticorps ic2, un fragment ou derive de celui-ci et compositions pharmaceutiques correspondantes - Google Patents

Methode de traitement de maladies neurodegeneratives mettant en oeuvre un anticorps ic2, un fragment ou derive de celui-ci et compositions pharmaceutiques correspondantes

Info

Publication number
FR2741088B1
FR2741088B1 FR9513576A FR9513576A FR2741088B1 FR 2741088 B1 FR2741088 B1 FR 2741088B1 FR 9513576 A FR9513576 A FR 9513576A FR 9513576 A FR9513576 A FR 9513576A FR 2741088 B1 FR2741088 B1 FR 2741088B1
Authority
FR
France
Prior art keywords
antibody
fragment
derivative
pharmaceutical compositions
neurodegenerative diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9513576A
Other languages
English (en)
Other versions
FR2741088A1 (fr
Inventor
Lazslo Tora
Yves Lutz
Yvon Trottier
Jean Louis Mandel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Priority to FR9513576A priority Critical patent/FR2741088B1/fr
Priority to PCT/FR1996/001773 priority patent/WO1997017445A1/fr
Publication of FR2741088A1 publication Critical patent/FR2741088A1/fr
Application granted granted Critical
Publication of FR2741088B1 publication Critical patent/FR2741088B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/028—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a herpesvirus

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
FR9513576A 1995-11-10 1995-11-10 Methode de traitement de maladies neurodegeneratives mettant en oeuvre un anticorps ic2, un fragment ou derive de celui-ci et compositions pharmaceutiques correspondantes Expired - Fee Related FR2741088B1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR9513576A FR2741088B1 (fr) 1995-11-10 1995-11-10 Methode de traitement de maladies neurodegeneratives mettant en oeuvre un anticorps ic2, un fragment ou derive de celui-ci et compositions pharmaceutiques correspondantes
PCT/FR1996/001773 WO1997017445A1 (fr) 1995-11-10 1996-11-08 Methode de traitement de maladies neurodegeneratives mettant en oeuvre un anticorps 1c2, un fragment ou derive de celui-ci et compositions pharmaceutiques correspondantes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9513576A FR2741088B1 (fr) 1995-11-10 1995-11-10 Methode de traitement de maladies neurodegeneratives mettant en oeuvre un anticorps ic2, un fragment ou derive de celui-ci et compositions pharmaceutiques correspondantes

Publications (2)

Publication Number Publication Date
FR2741088A1 FR2741088A1 (fr) 1997-05-16
FR2741088B1 true FR2741088B1 (fr) 1998-01-30

Family

ID=9484618

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9513576A Expired - Fee Related FR2741088B1 (fr) 1995-11-10 1995-11-10 Methode de traitement de maladies neurodegeneratives mettant en oeuvre un anticorps ic2, un fragment ou derive de celui-ci et compositions pharmaceutiques correspondantes

Country Status (2)

Country Link
FR (1) FR2741088B1 (fr)
WO (1) WO1997017445A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997042314A1 (fr) * 1996-05-08 1997-11-13 Cedars-Sinai Medical Center Acide nucleique codant pour l'heredo-ataxie cerebelleuse du type 2 et produits connexes
US6673535B1 (en) 1996-05-08 2004-01-06 Cedars-Sinai Medical Center Methods of detecting spinocerebellar Ataxia-2 nucleic acids
US6844431B1 (en) 1996-05-08 2005-01-18 Cedars-Sinai Medical Center Nucleic acid encoding spinocerebellar ataxia-2 and products related thereto
EP1001987B1 (fr) * 1997-08-01 2010-12-15 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Composition et nouveau procede pour depister les maladies dues a la formation d'agregats de proteines ou de fibrilles du type amyloide
EP1005654B1 (fr) 1997-08-01 2006-04-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Nouveau procede pour detecter des agregats de proteines ou des fibrilles du type amyloide
GB9726804D0 (en) * 1997-12-18 1998-02-18 Vlaams Interuniversitair Instu Mood disorder gene
FR2782167B1 (fr) * 1998-08-06 2000-11-03 Fond Jean Dausset Ceph Procede de classification de patients atteints de schizophrenie et identification d'une cible therapeutique potentielle pour cette maladie
WO2000024938A2 (fr) * 1998-10-27 2000-05-04 The Johns Hopkins University Repetitions ccg dans des adnc provenant du cerveau humain
CA2252727A1 (fr) * 1998-11-03 2000-05-03 Ridha Joober Polyglutamine contenant des proteines et son utilisation pour le diagnostic et le traitement de troubles neuropsychiatriques associes aux repetitions cag
US6630323B1 (en) * 1999-02-17 2003-10-07 The Board Of Trustees Of The Leland Stanford Junior University Naked cuticle genes and their uses
US6291652B1 (en) 2000-01-07 2001-09-18 The Regents Of The University Of California Antibodies specific for proteins having polyglutamine expansions
WO2011015572A1 (fr) 2009-08-03 2011-02-10 Galapagos Nv Cibles et composés moléculaires, et procédés pour leur identification utiles dans le traitement de maladies neurodégénératives

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834183A (en) * 1993-06-29 1998-11-10 Regents Of The University Of Minnesota Gene sequence for spinocerebellar ataxia type 1 and method for diagnosis

Also Published As

Publication number Publication date
WO1997017445A1 (fr) 1997-05-15
FR2741088A1 (fr) 1997-05-16

Similar Documents

Publication Publication Date Title
FR2741088B1 (fr) Methode de traitement de maladies neurodegeneratives mettant en oeuvre un anticorps ic2, un fragment ou derive de celui-ci et compositions pharmaceutiques correspondantes
MA26410A1 (fr) Formulations pharmaceutiques et procede pour leur production.
FR2722984B1 (fr) Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees
FR2737118B1 (fr) Composition dermatologique ou pharmaceutique, procede de preparation et utilisation
PT836390E (pt) Cigarro e metodo para o fabrico de cigarro para sistema electrico de fumar
FR2707882B1 (fr) Nouveaux kits thérapeutiques anti-médiateurs protéiques, procédé de préparation et compositions pharmaceutiques les renfermant.
BR9610598A (pt) Escova de dentes e método de sua manufatura
DE69633333D1 (de) Diphosphonatderivate von therapeutischen substanzen
NO971582L (no) Bearbeidet myseprotein og fremgangsmåte for fremstilling av dette
BR9601260A (pt) Produto absorvente absorvente higiênico e método de produção de um produto absorvente
AU7558796A (en) Fast-melt solid dosage form and method of making same
NO961483D0 (no) Fremgangsmåte for behandling av oljeholdig formasjon
DE69613386D1 (de) Carbostyrilderivat zur behandlung von ophthalmologischen erkrankungen
DZ2600A1 (fr) Associations pharmaceutiques d'amlodipine et d'unestatine et procédé pour leur préparation.
MC1998A1 (fr) Composes pour le traitement des maladies hyperproliferatibes et procede de preparation
FR2731708B1 (fr) Derives de piperidine, leur procede de preparation et leur application en therapeutique
EG21755A (en) Process for preparing of lercanidipine hydrochloride and their use for the treatment of angina and coronary disease
PL323177A1 (en) Azacycloalcane derivatives, method of obtaining them and their application for therapeutic purposes
EE9700198A (et) Meetod ja aparatuur orgaaniliste jäätmete töötlemiseks
AU4419596A (en) Method and reagent for prevention, inhibition of progression and regression of vascular diseases
NO973081L (no) Fremgangsmåte for behandling av kroniske progressive vaskulære sykdommer
DE69633857D1 (de) Gentechnologisch hergestelltes milbenantigen und herstellungsverfahren
NO306645B1 (no) Fremgangsmåte og innretning for forbrenning av avfall
MA26607A1 (fr) Utilisation de derives de piperidine et de pyrrolidine pour le traitement de maladies comprenant des formes de degenerescence neuronale et medicaments les contenant
MA26648A1 (fr) Associations thérapeutiques pour le traitement de maladies osseuses, et procédé pour leur préparation.

Legal Events

Date Code Title Description
ST Notification of lapse